Dasher Neuroscience Holdings (ROCO:7829) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7829 Dasher Neuroscience Holdings Inc ROCO:7829
22 GF Score
Price NT$56.30
! 2 Warning Signs
View Full Analysis

What is Dasher Neuroscience Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dasher Neuroscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$0.41 Mil. Dasher Neuroscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$0.00 Mil. Dasher Neuroscience Holdings's annualized EBITDA for the quarter that ended in Jun. 2026 was NT$-362.87 Mil. Dasher Neuroscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dasher Neuroscience Holdings's Debt-to-EBITDA or its related term are showing as below:

ROCO:7829's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64
* Ranked among companies with meaningful Debt-to-EBITDA only.

Dasher Neuroscience Holdings  (ROCO:7829) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Dasher Neuroscience Holdings Debt-to-EBITDA Related Terms

Dasher Neuroscience Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Dasher Neuroscience Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dasher Neuroscience Holdings Debt-to-EBITDA Chart

Dasher Neuroscience Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
- - - -

Dasher Neuroscience Holdings Semi-Annual Data
Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA - - - - -

ROCO:7829 vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dasher Neuroscience Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dasher Neuroscience Holdings Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dasher Neuroscience Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dasher Neuroscience Holdings's Debt-to-EBITDA falls into.


ROCO:7829
22GF Score
Dasher Neuroscience Holdings Inc ROCO:7829
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dasher Neuroscience Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dasher Neuroscience Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.811 + 0) / -404.55
=-0.00

Dasher Neuroscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.408 + 0) / -362.874
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Dasher Neuroscience Holdings Business Description

Address Park Street, 17th Floor., No.3, Nangang District, Taipei, TWN, 115603
Yoda Pharmaceuticals Inc is a pharmaceutical company specializing in using AI technology to develop drugs targeting Central Nervous System (CNS) disorders. The group provides solutions for Neurology, Neuropsychiatry, and Cerebrovascular Disease.
22GF Score

Get the complete analysis for ROCO:7829

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.30
Price